explore -WSS

explore

author：hotspot 2025-10-03 00:07:28 - browse：465

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Despite FDA concern, risk that CAR

WSS

What don’t we know about an Alzheimer’s drug side effect?

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

What to know about OceanGate, the company behind the missing Titanic submersible

Flagship Pioneering launches a new biotech in two countries

Retired US general questions alleged Putin, Prigozhin meeting

It's time to get medical device identifiers over the finish line

explore

explore

focus

What does generative AI mean for health care? We asked experts

Flagship Pioneering launches a new biotech in two countries

Cancer drug shortages should be causing more outrage

UnitedHealth’s Optum accused of antitrust violations in California

Supreme Court strikes down use of affirmative action

With clinical trial data readouts, here's how to spot spin

How one medical school became remarkably diverse

Retired US general questions alleged Putin, Prigozhin meeting

Hepatitis C has a cure — but many Americans still lack access to it

BIO selects John Crowley as new CEO

explore

How to pay for weight loss drugs and save Medicare

J&J to emphasize cancer drugs, stop much of its vaccine research

FDA investigates CAR

U.K. Biobank has 500,000 peoples' genome sequences available

Diagnostic tests are hitting their mathematical limits

What don’t we know about an Alzheimer’s drug side effect?

entertainment

hotspot

hotspot

knowledge